Normunity logo

Normunity Funding & Investors

West Haven, CT

Normunity is a biotechnology company creating a new class of precision immuno-oncology medicines, called immune normalizers, that target novel mechanisms that free the body’s normal immunity against cancer.Based on an ongoing, interactive academic-biotech alliance with the lab of Dr. Lieping Chen at Yale School of Medicine, Normunity is targetingnewly-discovered mechanisms of immune disruption in cancer based on proprietary discovery platforms that elucidate the complex interactions between human cancer and the immune system. The company is advancing an emerging pipeline of immune normalizers, including initial drug programs that target mechanisms that drive the exclusion of T-cells from immune-sensitive tumors and other mechanisms that are barriers to normal immune function in cancer.Normunity is located in Boston, Massachusetts and West Haven, Connecticut.

normunity.com

Total Amount Raised: $140,000,000

Normunity Funding Rounds

  • Series B

    $75,000,000

    Series B Investors

    Enavate Sciences
    Samsara BioCapital
    Pfizer Venture Investments
    Connecticut Innovations
    Regeneron Ventures
    YK Bioventures
    Osage Venture Partners
    Canaan Partners
    Taiho Ventures
    Sanofi Ventures
    HSG
  • Series A

    $65,000,000

    Series A Investors

    Canaan Partners
    Osage University Partners II
    Taiho Ventures
    Sanofi Ventures
Funding info provided by Diffbot.